kabutan

Sumitomo Pharma, The Current Fiscal Year Net Income Turns to Profit, Exceeds Expectations

Fri Jan 31, 2025 3:30 pm JST Earnings

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Earnings Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 31st (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a profit of 21.2 billion yen (compared to a loss of 117 billion yen in the same period last year).

In addition, the full-year consolidated net income has been revised upward from an expected loss of 16 billion yen to a profit of 16 billion yen (compared to a loss of 314 billion yen in the previous period), turning to a profit.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated net income for the October to March period (2H) is expected to increase 3.0 times, from the previous forecast of 16.2 billion yen to 48.2 billion yen (compared to a loss of 247 billion yen in the same period of the previous year).

In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a profit of 53.4 billion yen (compared to a loss of 49.9 billion yen in the same period last year). The operating profit/loss margin drastically improved from -37.9% in the same period last year to 19.0%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 460,265 -17,777 2,192 -18,502 -46.6 Jan 31, 2023 IFRS
Apr - Dec, 2023 235,028 -117,745 -105,191 -117,708 -296.3 Jan 31, 2024 IFRS
Apr - Dec, 2024 293,183 13,226 24,026 21,219 53.4 Jan 31, 2025 IFRS
YoY +24.7%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Prev 157,251 8,179 16,229 40.9 0 Oct 30, 2024 IFRS
Oct - Mar, 2024 New 200,251 29,179 48,229 121.4 0 Jan 31, 2025 IFRS
Revision Rate +27.3% +256.8% +197.2% +197.2%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 338,000 0 -16,000 -40.3 0 May 14, 2024 IFRS
Mar, 2025 New 381,000 21,000 16,000 40.3 0 Jan 31, 2025 IFRS
Revision Rate +12.7%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 161,916 -268,361 -266,987 -247,228 -622.3 0 May 14, 2024 IFRS
Oct - Mar, 2024 Guidance 200,251 29,179 48,229 121.4 0 Jan 31, 2025 IFRS
YoY +23.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 555,544 -76,979 -47,920 -74,512 -187.6 21 May 15, 2023 IFRS
Mar, 2024 314,558 -354,859 -323,114 -314,969 -792.8 0 May 14, 2024 IFRS
Mar, 2025 Guidance 381,000 21,000 16,000 40.3 0 Jan 31, 2025 IFRS
YoY +21.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 82,386 -31,247 -49,064 -49,967 -125.8 -37.9 Jan 31, 2024 IFRS
Jan - Mar, 2024 79,530 -237,114 -217,923 -197,261 -496.5 -298.1 May 14, 2024 IFRS
Apr - Jun, 2024 90,675 -3,105 17,203 15,937 40.1 -3.4 Jul 31, 2024 IFRS
Jul - Sep, 2024 90,074 -5,074 -49,609 -48,166 -121.2 -5.6 Oct 30, 2024 IFRS
Oct - Dec, 2024 112,434 21,405 56,432 53,448 134.5 19.0 Jan 31, 2025 IFRS
YoY +36.5%

Related Articles